protein pump inhibitor
While there are many regimens for the treatment of H. pylori infection, significant efforts in research and innovation have been made as well. The latest research results indicate that the new triple therapy comprising of amoxicillin, protein pump inhibitor (PPI) and levofloxacin has recorded the highest rate of eradication of this bacterial infection (Woo and Robinson, 2015). Alternatively known as hybrid therapy, it delays the overall duration of amoxicillin treatment for about 14 days (Woo and Robinson, 2015). Essentially, the prolonged treatment accounts for a significant percentage of H. pylori eradication by this hybrid therapy as well.
The prevalence resistance worldwide to the triple therapy has enhanced more effort on vonoprazan-based therapy, particularly in regions with a significantly limited rate of clarithromycin resistance. With the evolution of vonoprazan therapy, the treatment options and generally the eradication of helicobacter pylori problems are broadened (Chey et al, 2017). More profoundly, switching the vonoprazan as an acid blocker for H. pylori means that there is a chance for a further reassessment of the triple therapy. It equally improves the efficacy of triple therapy through a significant reduction to the resistance in clarithromycin as previously noted. Additionally, concomitant therapy has also been introduced for the reduction of the metronidazole resistance estimated to be about 50% in Asian countries (Woo and Robinson, 2015). Concomitant therapy implies using conventional antibiotics to reduce resistance levels in triple therapy
